Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
Background: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal ® Dispersion form...
Saved in:
Main Authors: | Marjie L. Hard (Author), Angela Wehr (Author), Lisa von Moltke (Author), Yangchun Du (Author), Sarah Farwick (Author), David P. Walling (Author), John Sonnenberg (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021) -
Schizophrenia: effects of aripiprazole in metabolic syndrome
by: Deborah Galvão Coelho da Silva, et al.
Published: (2019) -
Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
by: Bhanu Gupta, et al.
Published: (2021) -
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
by: Michele Wilson, et al.
Published: (2016) -
The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021)